the programme

ESMO Preceptorship Programme
Prostate Cancer
Multidisciplinary management, standards of care,
therapeutic targets and future perspectives
9-10 April 2015, Prague, Czech Republic
CO-CHAIRS
Chair: Alan Horwich, UK
Co-Chair: Gedske Daugaard,DK
FACULTY
Ferran Algaba, ES
Gert Attard UK
Gedske Daugaard, DK
Winauld Gerritsen NL
Theo M. de Reijke, NL
Valerie Fontayne, BE
LEARNING OBJECTIVES



To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to
heterogeneity in prostate cancer
To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
To learn about advances in treatment and novel targets in prostate cancer
Thursday, 9 April 2015
09:00-09:15
15’
15’
Opening and Welcome
Welcome from ESMO, objectives and scientific introduction
Alan Horwich, UK
09:15-10:30
80’
25’
20’
20’
15’
Session 1
Screening, diagnosis and staging
Diagnosis , and impact of pathology and genetic changes on prognosis
Screening, investigations and staging classification
Carcinogenesis, aetiology and familial genetics
Discussion
Chairs: Alan Horwich, UK and
Thomas Wiegel, DE
Ferran Algaba, ES
Theo M. de Reijke, NL
Ferran Algaba, ES
10.35–10.45
Break
10:45-12:30
105’
20’
Session 2
Localised prostate cancer
Role of radiotherapy
Chair: Ferran Algaba, ES and
Gedske Daugaard, DK
Valerie Fontayne, BE
20’
20’
3x15’
Role of surgery
Active surveillance
3 x Clinical cases from participants:
Theo M. de Reijke, NL
Alan Horwich, UK
All Faculty
Each 15 min slot for clinical cases comprises 7’ case presentation plus 8’ Q&A/ panel discussion
12:45-13:45
Lunch
13:45-15:15
90’
10’
10’
20’
Session 3
Advanced prostate cancer
Presentation with lymphadenopathy
Urinary obstruction
Value and role of PSA as a tumor marker of response/relapse
Debate: This house believes that locally-advanced prostate cancer should
be treated with radiotherapy and hormone deprivation
Argument For
Argument Against
2 x Clinical cases from participants:
10’
10’
2x15’
Chair: Alan Horwich, UK and
Winauld Gerritsen, NL
Theo M. de Reijke, NL
Theo M. de Reijke, NL
Gedske Daugaard, DK
Valerie Fonteyne, BE
Theo M. de Reijke, NL
All Faculty
Each 15 min slot for clinical cases comprises 7’ case presentation plus 8’ Q&A/ panel discussion
15:15 – 15:45
15:45-17:15
90’
30’
30’
2x15’
Break
Session 4
Initial and second-line hormone therapies
First-line hormone therapy for metastatic disease; role and toxicities
Further hormone therapies incl. Abiraterone and Enzalutamide
2 x Clinical cases from participants:
Chair: Thomas Wiegel, DE and
Gedske Daugaard, DK
Alan Horwich, UK
Gert Attard, UK
All Faculty
Each 15 min slot comprises 7’ case presentation plus 8’ Q&A/ panel discussion
19:30-22:00
Dinner
Friday, 10 April 2015
09.00-10:15
75’
25’
25’
25’
10:15 – 10:30
Session 5
Castration refractory prostate cancer
First and second-line chemotherapy
Bone targeting (Bisphosphonates and RANK Ligands)
Isotope therapies
Chair: Gert Attard, UK and
Theo M. de Reijke, NL
Gedske Daugaard, DK
Winauld Gerritsen, NL
Alan Horwich, UK
Coffee break
10:30-11:45
75’
30’
30’
15’
Session 6
New drugs and targets, including immunotherapy
Immunotherapy
New targets and drugs in current development
Discussion
Chair: Gedske Daugaard, DK and
Alan Horwich, UK
Winauld Gerritsen, NL
Gert Attard, UK
11:45-12:30
45’
2x15’
15’
Session 7
Case presentations & take home messages
2 x Clinical cases from participants:
Closing remarks and take-home messages
Chairs: Winauld Gerritsen, NL
and Gert Attard, UK
All Faculty
Alan Horwich, UK
Each 15 min slot comprises 7’ case presentation plus 8’ Q&A/ panel discussion
12:30-13:15
Standing lunch and departure